HomeGemfibrozilGemfibrozil + Pioglitazone And Glimepiride

Does Gemfibrozil Interact with Pioglitazone And Glimepiride?

Gemfibrozil and Pioglitazone And Glimepiride have a major drug interaction according to U.S. FDA drug labeling data. Strong CYP2C8 inhibitor significantly increases pioglitazone exposure and half-life. Maximum pioglitazone dose must be limited to 15 mg daily. The mechanism involves cyp2c8 inhibition increases pioglitazone auc and half-life. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Gemfibrozil Class
Peroxisome Proliferator Receptor alpha Agonist
Pioglitazone And Glimepiride Class
Sulfonylurea
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Gemfibrozil and Pioglitazone And Glimepiride occurs because cyp2c8 inhibition increases pioglitazone auc and half-life. Clinically, this means strong cyp2c8 inhibitor significantly increases pioglitazone exposure and half-life. maximum pioglitazone dose must be limited to 15 mg daily. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Gemfibrozil and your doctor is considering prescribing Pioglitazone And Glimepiride (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Gemfibrozil(Lopid)+💊 Pioglitazone And Glimepiride(Duetact)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Peroxisome Proliferator Receptor alpha Agonist
Drug B class
Sulfonylurea
Source
NLP:pioglitazone and glimepiride

What this means in plain English

Strong CYP2C8 inhibitor significantly increases pioglitazone exposure and half-life. Maximum pioglitazone dose must be limited to 15 mg daily.

About Gemfibrozil and Pioglitazone And Glimepiride

Gemfibrozil is a Peroxisome Proliferator Receptor alpha Agonist, while Pioglitazone And Glimepiride is a Sulfonylurea. You may recognize them by the brand names Lopid and Duetact. Both medications are taken by mouth. Both Gemfibrozil and Pioglitazone And Glimepiride carry an FDA boxed warning — the agency's most serious safety designation.

What the FDA label says

"CYP2C8 inhibition increases pioglitazone AUC and half-life"

📖 Source: NLP:pioglitazone and glimepiride

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Gemfibrozil and Pioglitazone And Glimepiride against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.